These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 39156888)

  • 1. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.
    Abdelnabi MN; Hassan GS; Shoukry NH
    Front Immunol; 2024; 15():1437046. PubMed ID: 39156888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment.
    Booijink R; Ramachandran P; Bansal R
    Trends Pharmacol Sci; 2024 Jul; 45(7):614-627. PubMed ID: 38853100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis.
    Saito T; Tsuchishima M; Tsutsumi M; George J
    J Cell Mol Med; 2024 Jun; 28(12):e18491. PubMed ID: 38894579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The "Domino effect" in MASLD: The inflammatory cascade of steatohepatitis.
    Mladenić K; Lenartić M; Marinović S; Polić B; Wensveen FM
    Eur J Immunol; 2024 Apr; 54(4):e2149641. PubMed ID: 38314819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD.
    Schilcher K; Dayoub R; Kubitza M; Riepl J; Klein K; Buechler C; Melter M; Weiss TS
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Immunity and MASLD.
    Meyer M; Schwärzler J; Jukic A; Tilg H
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of immune dysregulation in MASLD.
    Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
    Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.
    Mori T; Yoshio S; Kakazu E; Kanto T
    Gastroenterol Rep (Oxf); 2024; 12():goae089. PubMed ID: 39411101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease.
    Li H; Xia N
    Front Immunol; 2024; 15():1447391. PubMed ID: 39372417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.